about
Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advancesChinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthmaChinese expert consensus on clinical use of non-invasive airway inflammation assessment in bronchial asthmaPhenotypes, Risk Factors, and Mechanisms of Adult-Onset AsthmaBiomarkers and severe asthma: a critical appraisalPeriostin and TGF-β-induced protein: Two peas in a pod?Profile of lebrikizumab and its potential in the treatment of asthmaIL-4 and IL-13 signaling in allergic airway diseaseThe cell biology of asthmaPeriostin: its role in asthma and its potential as a diagnostic or therapeutic targetImmune signatures of pathogenesis in the peritoneal compartment during early infection of sheep with Fasciola hepaticaPatient profiles and clinical utility of mepolizumab in severe eosinophilic asthma.Revisiting the matricellular concept.Expression and pathological effects of periostin in human osteoarthritis cartilageMatrix metalloproteinase 14 is required for fibrous tissue expansionMesenchymal stem cells suppress lung inflammation and airway remodeling in chronic asthma rat model via PI3K/Akt signaling pathway.Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localizationPeriostin - A Novel Systemic Biomarker for Eosinophilic Airway Inflammation: A Case Control StudyThe Clinical and Health Economic Value of Clinical Laboratory DiagnosticsAssociation between IL-13 +1923C/T polymorphism and asthma risk: a meta-analysis based on 26 case-control studies.TH9 cell differentiation, transcriptional control and function in inflammation, autoimmune diseases and cancer.Omalizumab for severe asthma: efficacy beyond the atopic patient?Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis.Integrating personalized gene expression profiles into predictive disease-associated gene poolsImplications of the inflammatory response for the identification of biomarkers of chronic obstructive pulmonary disease.Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects.Lebrikizumab in the treatment of asthma.Commonality of the IL-4/IL-13 pathway in atopic diseases.Immunological profiling of patients with ulcerative colitis leads to identification of two inflammatory conditions and CD1a as a disease markerInnovative treatments for severe refractory asthma: how to choose the right option for the right patient?Influence of IL13 on Periostin Secretion by Synoviocytes in Osteoarthritis.Pregnancy-associated plasma protein-A (PAPP-A) levels in patients with severe allergic asthma are reduced by omalizumab.Characterization of a sandwich ELISA for the quantification of all human periostin isoforms.LIGHT-HVEM signaling in keratinocytes controls development of dermatitis.Diagnostic significance of serum periostin in eosinophilic chronic sinusitis with nasal polyps.Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease.Sputum periostin in patients with different severe asthma phenotypes.Circulating periostin level in asthmatic pregnancy.Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD.Nonallergic Asthma and Its Severity: Biomarkers for Its Discrimination in Peripheral Samples.
P2860
Q26750424-F296045E-C0C5-438E-8BA9-828ED85F1DAAQ26771615-C480232F-8864-4657-892E-9503F6DF62A8Q26772201-E5094ABF-56D1-431F-96FB-362A6C8FC5AFQ26779940-17F69340-62DE-4E5E-ADAF-E0DB4AD7B402Q26782718-60E344FB-8093-4B55-B480-B3615370ABFEQ26796543-838BCECA-58CE-4D8D-9697-302530F514E9Q26797198-0C5E1C8C-C513-4DF3-A9C5-F30433DA84B7Q26859510-57FFF2C9-B405-4716-A130-9B48A8ACAF4DQ27009449-147D68C9-6789-4439-BB29-8A1D6B40279CQ27021972-49FBC52C-0C48-409F-8C7C-B1CAF713E8F5Q33765735-AD46A02D-0B3E-43F6-A933-63AF787F04EAQ33876003-210E40AE-28F9-4261-ACA7-D6F7DA0ADAC1Q35233858-635F2465-B7EE-4985-9913-B69202840727Q35750612-012F446B-51BA-4D52-A66B-EE3A4B5A55EBQ35781999-DF582CBB-6B52-4F1D-9370-52CE9DC71CB3Q36095102-C9510AE4-91AE-4E3B-B7A5-314A6684920DQ36578825-98893243-6CB2-40D6-9682-7E4D2C4B556DQ36708547-FD1B3DF2-EE6C-45B2-9F56-2F0A56880AC0Q37155167-FF35B126-7BA1-4E4D-BEF2-765614D59134Q37609807-B6B3DC35-D68C-4189-84B6-417AB30C7596Q37688655-EBA1E54A-5AC4-468F-826F-F884D0A388F6Q38201304-AF2A3BD6-DF1E-44C1-9D41-C62695FAB661Q38442822-8EEE411C-7CB9-4481-9345-F3BD2B50C8EEQ38709521-ECE7EC81-4C99-4DE9-B4D8-FC25F24FA443Q38710985-2314A1D1-8F4E-49AB-93EF-F2673072D5CDQ38820261-A65AB7A1-F52A-4517-8ABA-6C9742580D30Q38830570-ED92D67F-256C-4387-A87C-2534DC6B1EC3Q39170851-8CD694A1-6314-42A7-AFCD-FF4C82A54DFFQ39220077-B5754A48-B663-4978-AF82-BEDD465AB84AQ41633977-3BD947BA-5AC8-4111-BD6D-418D9AC71ABCQ42315900-F7F17E92-FC41-4DE9-BAFB-943DDA7A2E45Q47324073-21070C18-E15C-4ADF-B9BE-34F39F2C3E09Q47895182-8332C625-221F-4BE5-B64B-66A921E9B41AQ48232493-E482783D-1D26-4BC2-8A0D-48DC9C22BF9BQ48617322-39416155-6453-47C7-94E5-81C1B388BDD1Q49201946-5496A5D5-189E-4694-83D2-12CFE290754CQ51663505-80E6419C-2C6E-4400-BB42-52DB41B63BDEQ51683742-73048D2E-8E95-4AD1-9AA2-2FFCB00C3BB3Q55049104-7C5931F3-7A89-4CCA-B277-1207EDD105F8Q55417740-6A706368-57EF-42E8-9F02-CC00FF6A141D
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Periostin, a novel biomarker of TH2-driven asthma.
@en
type
label
Periostin, a novel biomarker of TH2-driven asthma.
@en
prefLabel
Periostin, a novel biomarker of TH2-driven asthma.
@en
P1476
Periostin, a novel biomarker of TH2-driven asthma.
@en
P2093
Mustafa A Atik
P356
10.1097/MCP.0000000000000005
P577
2014-01-01T00:00:00Z